- Home
- DOMH vs CNTX Comparison
DOMH vs CNTX Comparison
Compare DOMH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- CNTX
- Stock Information
- Founded
- DOMH 1967
- CNTX 2015
- Country
- DOMH United States
- CNTX United States
- Employees
- DOMH N/A
- CNTX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- CNTX Health Care
- Exchange
- DOMH Nasdaq
- CNTX Nasdaq
- Market Cap
- DOMH 83.3M
- CNTX 78.0M
- IPO Year
- DOMH N/A
- CNTX 2021
- Fundamental
- Price
- DOMH $5.27
- CNTX $0.64
- Analyst Decision
- DOMH
- CNTX Strong Buy
- Analyst Count
- DOMH 0
- CNTX 5
- Target Price
- DOMH N/A
- CNTX $5.50
- AVG Volume (30 Days)
- DOMH 302.6K
- CNTX 312.3K
- Earning Date
- DOMH 08-07-2025
- CNTX 08-06-2025
- Dividend Yield
- DOMH 6.07%
- CNTX N/A
- EPS Growth
- DOMH N/A
- CNTX N/A
- EPS
- DOMH N/A
- CNTX N/A
- Revenue
- DOMH $24,891,000.00
- CNTX N/A
- Revenue This Year
- DOMH N/A
- CNTX N/A
- Revenue Next Year
- DOMH N/A
- CNTX N/A
- P/E Ratio
- DOMH N/A
- CNTX N/A
- Revenue Growth
- DOMH 630.80
- CNTX N/A
- 52 Week Low
- DOMH $0.83
- CNTX $0.49
- 52 Week High
- DOMH $13.58
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- DOMH 49.52
- CNTX 46.34
- Support Level
- DOMH $5.08
- CNTX $0.62
- Resistance Level
- DOMH $6.08
- CNTX $0.70
- Average True Range (ATR)
- DOMH 0.53
- CNTX 0.04
- MACD
- DOMH -0.04
- CNTX 0.01
- Stochastic Oscillator
- DOMH 25.45
- CNTX 42.86
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.